INTRODUCTION AND OBJECTIVES: Multiparametric magnetic resonance imaging (mpMRI) with and without targeted biopsy has been suggested to improve risk assessment over systematic standard biopsy for prostate cancer (PCa). We aim to compare histologic upgrading between prostate biopsy and radical prostatectomy (RP) in men with and without prostate mpMRI prior to biopsy.
METHODS: We examined our PCa database from October 2014 to June 2017 and identified 363 men who underwent RP within one year of diagnostic biopsy. Men with 3-Tesla mpMRI prior to biopsy were compared to men who had not had prior MRI (mpMRI 155, no MRI 208) . All mpMRI were reported using the Prostate Imaging Reporting and Data System (PIRADS). All men received a systematic standard template prostate biopsy, and men with prior mpMRI and PIRADS classification 3 to 5 lesions underwent additional MRI targeted biopsy using the UroNav platform. For our analysis, we compared the highest Gleason grade group (GGG) at biopsy and at RP pathologic analysis. Men were sub-stratified based on NCCN criteria using biopsy GGG and PSA into low-risk, intermediate-favorable-risk, intermediate-unfavorable-risk, high-risk, and very-high-risk categories. Men with prior mpMRI were also sub-stratified based on highest PIRADS classification.
RESULTS: Overall, there was no difference between the prior mpMRI and no MRI cohorts in pre-biopsy PSA (9.0 vs 8.7, p[0.96), biopsy GGG (p[0.40), and RP GGG (p[0.81) . Men with prior mpMRI were older (65.3 vs 62.1, p<0.01) and less likely to be biopsy naive (52.3% vs 74.5%, p<0.01). We found no significant differences in histologic upgrading (29.7% vs 27.4%, p[0.64) between the prior mpMRI and no MRI cohorts. No differences in histologic upgrading were found when men were stratified into risk groups based on NCCN criteria (Figure 1 ). Further examination of the prior mpMRI cohort revealed that increasing PIRADS classification did not correlate with histologic upgrading rate (Figure 1) . CONCLUSIONS: Although prostate mpMRI is a useful tool in the diagnosis and management of PCa, we found histologic upgrading between biopsy and RP was not significantly impacted by prostate mpMRI. For men planning to undergo prostatectomy after standard biopsy, preoperative prostate mpMRI with subsequent targeted biopsy does not provide a diagnostic benefit. METHODS: Retrospective analysis of 588 consecutive patients with biopsy-proven CaP and mpMRI prior to radical prostatectomy at a single tertiary institution from June 2010 to February 2018. We correlated co-registered mpMRI lesions with whole mount prostatectomy specimens. We calculated mpMRI sensitivity detecting individual CaP and clinically significant CaP foci (any Gleason Grade greater than 1) and predictors of tumor detection using multivariate analysis.
RESULTS: Final analysis included 1213 pathologicallyconfirmed tumor foci in 588 patients with primarily intermediate (75%) or high risk (12%) CaP. mpMRI detected 45% (95% CI; 42-47%) of all lesions, including 65% (95% CI; 61-69%) of clinically significant lesions. 74% and 31% of missed solitary and multifocal tumors were clinically significant, respectively. While the majority of missed lesions were small (61.1% 1 cm), 28.3% were between 1-2 cm, and 10.4% > 2cm. mpMRI missed at least one clinically significant foci in 34% of patients, including in 45% with multifocal lesions. On multivariate analysis, smaller, low-grade, multi-focal, non-index tumors in men with lower PSA-density were more likely to be missed. Limitations include imperfect co-registration process and uncertain clinical significance of undetected lesions.
CONCLUSIONS: mpMRI detects less than half of all and less than two-thirds of clinically significant CaP foci. The moderate perlesion sensitivity and significant proportion with undetected tumor foci demonstrate the current limitations of mpMRI. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e423
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